BACKGROUND Genome-wide association studies (GWAS) have significantly contributed to the association of many clinical conditions and phenotypic characteristics with genomic variants. The majority of these genomic findings have been deposited to the GWAS catalog. So far, findings uncovering associations of single nucleotide polymorphisms (SNPs) with treatment efficacy in mood disorders are encouraging, but not adequate. METHODS Statistical, genomic, and literature information was retrieved from EBI's GWAS catalog, while we also searched for potential clinical information/clinical guidelines in well-established pharmacogenomics databases regarding the assessed drug-SNP correlations of the present study. RESULTS Here, we provide an overview of significant genome-wide associations of SNPs with the response to commonly prescribed antipsychotics and antidepressants. Up to date, this is the first study providing novel insight in previously reported pharmacogenomics associations for antipsychotic/antidepressant treatment. We also show that although there are published CPIC guidelines for antidepressant agents, as well as the FDA labels include genome-based drug prescription information for both antipsychotic and antidepressant treatments, there are no specific clinical guidelines for the assessed drug-SNP correlations of this study. CONCLUSIONS Our present findings suggest that more effort should be implemented towards identifying GWA-significant antipsychotic and antidepressant pharmacogenomics correlations. Moreover, additional functional studies are required in order to characterise the potential role of the assessed SNPs as biomarkers for the response of patients to antipsychotic/antidepressant treatment.

中文翻译：

---

描绘变体与抗精神病药和抗抑郁药治疗反应之间的重要全基因组关联：对临床药物基因组学的影响。

背景技术全基因组关联研究（GWAS）极大地促进了许多临床状况和表型特征与基因组变异的关联。这些基因组发现的大部分已保存在GWAS目录中。到目前为止，发现单核苷酸多态性（SNPs）与情绪障碍治疗效果相关性的研究结果令人鼓舞，但并不充分。方法从EBI的GWAS目录中检索统计，基因组和文献信息，与此同时，我们还在完善的药物基因组学数据库中搜索有关本研究评估的药物与SNP相关性的潜在临床信息/临床指南。结果在这里，我们概述了SNP与全基因组抗精神病药和抗抑郁药的反应之间的重要全基因组关联。迄今为止，这是第一项针对先前报道的抗精神病药/抗抑郁药的药物基因组学协会提供新颖见解的研究。我们还表明，尽管已经发布了有关抗抑郁药的CPIC指南，并且FDA标签包括针对抗精神病药和抗抑郁药的基于基因组的药物处方信息，但尚无针对此研究评估的药物SNP相关性的特定临床指南。结论我们目前的发现表明，应该在确定GWA显着的抗精神病药和抗抑郁药的药物基因组学相关性方面付出更多的努力。此外，